Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Quinazolines
  • Receptor, Epidermal Growth Factor
  • Receptor, ErbB-2

abstract

  • Lapatinib as a monotherapy or in combination with capecitabine seems to be equally effective in patients with p95HER2-positive and p95HER2-negative HER2-positive breast tumors.

publication date

  • May 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3243489

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-09-3407

PubMed ID

  • 20406840

Additional Document Info

start page

  • 2688

end page

  • 95

volume

  • 16

number

  • 9